ST Pharm Secures Japanese Patent for Key LNP Material 'STP1244'
by Park Jeongyeon
Published 13 Apr.2026 09:22(KST)
Securing Rights from Key Raw Materials to Formulation
"Enhancing CDMO Competitiveness to Respond to the mRNA Vaccine and Therapeutics Market"
ST Pharm announced on April 13 that it has completed registration of a Japanese patent for the ionizable lipid 'STP1244', a key raw material in its proprietary mRNA-LNP platform 'STLNP', as well as for the LNP formulation (STL1244) that uses this material.
This is the first registered patent among those related to the STLNP platform. Ionizable lipids are substances that enhance the intracellular delivery efficiency of mRNA and promote endosomal escape, making them a core component that determines the performance of LNPs. With this registration, ST Pharm has secured a technology portfolio covering everything from key raw materials to the finished formulation. Currently, additional patent reviews are underway in nine countries, including Korea, the United States, Europe, and China.
A representative from ST Pharm stated, "Following the Japanese patent registration for 'SmartCap' last March, the registration for STLNP means we now possess both core platform technologies for mRNA drug development," adding, "We will expand our role in the development of mRNA cancer vaccines and mRNA-based in-vivo CAR-T therapies."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.